ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS

Area of Science:

• Biotechnology
• Pharmacogenomics
• Health Policy

Background:

• Companion diagnostic tests (CDx) are essential for personalized medicine, guiding therapy selection based on individual biomarkers.
• The growing number of drugs requiring CDx presents significant regulatory and reimbursement challenges worldwide.
• The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted an environmental scan to address these issues.

Purpose of the Study:

• To assess the current landscape and future trends of companion diagnostic (CDx) tests.
• To identify challenges and opportunities in regulatory and reimbursement policies for CDx.
• To inform policy development regarding the clinical use and funding of CDx.

Main Methods:

• An environmental scan was performed.
• A focused literature search was conducted.
• Feedback was solicited from targeted stakeholders.

Main Results:

• The global CDx market is projected to grow at approximately 20% CAGR by 2030.
• Factors influencing CDx adoption include potential cost-savings from reduced treatment failures and adverse reactions.
• Regulatory frameworks have been updated in countries like the US, while reimbursement policies vary, with Canada lacking specific policies for co-dependent technologies.

Conclusions:

• The CDx market is poised for substantial future expansion, driven by increased understanding of biomarkers and potential cost-effectiveness.
• Health technology assessment (HTA) is vital for informing policies on the clinical utility and reimbursement of pharmaceuticals utilizing CDx.
• Evaluating the realization of CDx benefits is critical for guiding future healthcare decisions and investments.